HC Wainwright Cuts Tetraphase Pharmaceuticals (TTPH) Price Target to $6.00

Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its target price decreased by research analysts at HC Wainwright from $17.00 to $6.00 in a report issued on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 10.50% from the company’s previous close.

Other research analysts also recently issued reports about the stock. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $11.00 target price on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $12.63.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $5.43 on Wednesday. The firm has a market cap of $281.71, a P/E ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a 1 year low of $4.91 and a 1 year high of $9.93.

In related news, Director L Patrick Gage acquired 3,880 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total transaction of $54,425.00. Following the transaction, the insider now directly owns 8,750 shares in the company, valued at $54,425. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Tetraphase Pharmaceuticals by 21.2% during the fourth quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock valued at $25,479,000 after purchasing an additional 707,296 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Tetraphase Pharmaceuticals by 54.4% in the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after acquiring an additional 900,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after acquiring an additional 230,420 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after acquiring an additional 360,552 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Tetraphase Pharmaceuticals in the third quarter valued at approximately $7,915,000. 58.28% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/hc-wainwright-cuts-tetraphase-pharmaceuticals-ttph-price-target-to-6-00.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply